Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Metformin Stories

FDA Approves Novel AstraZeneca, Bristol-Meyers Squibb Diabetes Drug
2014-01-10 11:37:58

Ranjini Raghunath for redOrbit.com - Your Universe Online The FDA has approved the use of a new Type 2 diabetes drug called Farxiga, developed by pharmaceutical companies Bristol-Meyers Squibb and AstraZeneca. Type 2 diabetes affects 24 million people in the US and nearly 350 million people worldwide. Conventional diabetes drugs work by reducing the amount of sugar the body absorbs from food or by boosting the production of insulin which disposes of excess sugar. Farxiga, however,...

2013-12-23 16:23:01

DALLAS, Dec. 23, 2013 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds Research Report on Research Report on China Antidiabetic Drug Market, 2014-2018 to its store that says in 2013, the revenue of global diabetes treatment market exceeded USD 40 billion. The CAGR is expected to be 5% or more in next few years. (Photo: http://photos.prnewswire.com/prnh/20131223/MN37633) In 2013, the diabetes prevalence rate of grown-ups aged in 20 to 79 was 8.3% in the globe. The number...

2013-12-20 12:24:35

DUBLIN, Dec. 20,2013. /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/zrrwvb/research_report) has announced the addition of the "Research Report on China's Diabetes Drug Market, 2013-2017" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Diabetes refers to a series of metabolic disorder syndrome such as sugars, proteins, fat, water and electrolyte that are triggered by islet dysfunction and insulin resistance, and...

2013-12-17 11:18:57

Treatment with the diabetes drug metformin appears to be associated with a modest reduction in body mass index (BMI) in obese children when combined with lifestyle interventions such as diet and exercise, according to a study by Marian S. McDonagh, Pharm. D., of the Oregon Health & Science University, and colleagues. Childhood obesity is a health problem in the United States, with nearly 17 percent of children being obese. Metformin is approved by the Food and Drug Administration to...

2013-12-16 08:25:44

--Supports Completion of Ongoing Clinical Studies and Preparations for Further Trials of Microbiome Modulator NM504 for Prediabetes and Type 2 Diabetes-- BROOMFIELD, Colo., Dec. 16, 2013 /PRNewswire/ -- MicroBiome Therapeutics(TM) LLC, (MBT) today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in...

2013-12-12 20:24:44

RARITAN, N.J., Dec. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. The complete response letter related to the NDA requested additional information to support the comparability of the twice-daily...

diabetes med affects men's and women's hearts differently
2013-12-12 15:24:01

Brett Smith for redOrbit.com - Your Universe Online In a new study from researchers at at Washington University School of Medicine, the type 2 diabetes drug metformin was found to have different effects on the hearts of men and women, despite managing blood sugar the same in both sexes. According to the study, which was published in the December issue of the American Journal of Physiology - Heart and Circulatory Physiology, the drug had positive effects on women’s heart health, but...

2013-12-10 23:19:52

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being...

2013-12-10 23:19:45

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked...

2013-12-10 23:19:39

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked...